Synthetic lethality in cancer drug discovery: challenges and opportunities
Hartwell, L. H., Szankasi, P., Roberts, C. J., Murray, A. W. & Friend, S. H. Integrating genetic approaches…
How a change in FDA guidance might revolutionise MASH drug development
Transformative new shifts have taken place in the last month in the metabolic dysfunction-associated steatohepatitis (MASH) therapy space,…
Join Sept. 18 with George Church and this year’s top biotech startups
I asked AI the other day how many biotechs have been co-founded by Harvard’s George Church. About 50…
Europe moves to reject embattled Duchenne gene therapy
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at…
First New PTSD Drug in Two Decades On the Horizon?
The Psychopharmacologic Drugs Advisory Committee of the FDA is set to meet on July 18 to consider a…
Where Are All the AI Drugs?
A new drug usually starts with a tragedy. Peter Ray knows that. Born in what is now Zimbabwe,…
FDA focuses attention on rejected drug decisions
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at…
Americans must stop subsidizing the price of drugs in other countries
President Trump is right that Americans often pay too much for prescription drugs, and that other countries aren’t…
HS Genetics Point Toward the Hair Growth Cycle
A missense variant in WNT10A detected by a recent genome-wide association study (GWAS) in hidradenitis suppurativa (HS) suggested…
FDA denies Barth syndrome drug approval, suggests accelerated pathway
For the past decade, Stealth BioTherapeutics has ridden a rollercoaster trying to convince the Food and Drug Administration…